Drug intelligence / Profile preview

Neopeptine Forte

Development stage: Unknown
Lead developer: Raptakos Brett
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral

Overview

Neopeptine Forte is a multi-ingredient digestive aid developed and marketed by Raptakos Brett & Company Ltd. It is formulated as an oral liquid containing a combination of digestive enzymes—Alpha Amylase, Diastase, and Papain—alongside carminative oils including Anise, Caraway, and Dill oils. The enzymatic components facilitate the breakdown of complex carbohydrates (starches) and proteins into simpler, absorbable units, while the carminative oils assist in the expulsion of gas and reduce gastrointestinal spasms. Neopeptine Forte is primarily indicated for the relief of symptoms associated with indigestion, such as bloating, flatulence, and abdominal discomfort, and is widely marketed in India.

Brand names: Neopeptine Forte

Beyond the preview

Go deeper on Neopeptine Forte.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neopeptine Forte.

Explore the full profile